Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUSNHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to Share XScotland backs NHS use of Alexion’s Ultomiris for rare disease aHUShttps://pharmaphorum.com/news/scotland-backs-nhs-use-of-alexions-ultomiris-for-rare-disease-ahus/
Alexion trials rare disease drug Ultomiris in severe COVID-19 casesPharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined Share XAlexion trials rare disease drug Ultomiris in severe COVID-19 caseshttps://pharmaphorum.com/news/alexion-trials-rare-disease-drug-ultomiris-in-severe-covid-19-cases/
Alexion’s biosimilar-blocking EU patent play for Soliris failsThe European Patent Office has blocked an attempt by Alexion to extend the patent protection for its blockbuster Share XAlexion’s biosimilar-blocking EU patent play for Soliris failshttps://pharmaphorum.com/news/alexions-biosimilar-blocking-eu-patent-play-for-soliris-fails/
Alexion’s Soliris follow-up Ultomiris snares EU approvalAlexion has the EU approval it needed for Ultomiris, a follow-up to its rare disease therapy Soliris that Share XAlexion’s Soliris follow-up Ultomiris snares EU approvalhttps://pharmaphorum.com/news/alexions-soliris-follow-up-ultomiris-snares-eu-approval/
Seven future blockbuster drugs to look out for in 2019AbbVie’s rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch Share XSeven future blockbuster drugs to look out for in 2019https://pharmaphorum.com/news/seven-future-blockbuster-drugs-to-look-out-for-in-2019/
